BPC-157 Oral Capsules deliver the Body Protection Compound-157 through the gastrointestinal tract — a route of administration that, paradoxically, makes BPC-157 uniquely effective for GI conditions. While injectable BPC-157 distributes systemically and must reach the gut from the bloodstream, oral BPC-157 passes directly through the GI lumen in contact with the mucosal surface, making it the first-choice format for gut-targeted healing protocols.

The GI Stability Paradox

BPC-157's oral bioavailability for systemic effects is debated — the peptide may undergo partial degradation in the stomach. However, this apparent weakness becomes a therapeutic advantage for GI applications: the peptide remains at therapeutic concentrations in the GI lumen (stomach, small intestine, large intestine) while in transit, producing local healing effects directly at the mucosal surface before any absorption question arises.

The original BPC-157 research by Dr. Predrag Sikiric's group at the University of Zagreb used both oral and injected routes, finding both effective for GI conditions — with the oral route providing particularly convenient and well-tolerated GI-specific therapeutic coverage.

Conditions Where Oral BPC-157 Is the Preferred Format

1. Leaky Gut Syndrome (Intestinal Permeability): BPC-157 upregulates tight junction proteins (ZO-1, ZO-2, occludin, claudin) that maintain the integrity of the intestinal epithelial barrier. In the oral format, these effects are delivered directly to the compromised junction sites throughout the gut lining.

2. IBD (Inflammatory Bowel Disease) — Crohn's and Colitis: Animal models of IBD show BPC-157 reduces mucosal inflammation, promotes ulcer healing, and restores normal bowel motility. The oral route delivers anti-inflammatory peptide directly to inflamed intestinal mucosa.

3. GERD and Esophageal Damage: BPC-157 promotes esophageal healing in acid damage models — oral capsules allow contact with the esophageal and gastric mucosa during capsule transit.

4. Peptic and Duodenal Ulcers: BPC-157 was first characterized for its gastric cytoprotective effects — promotion of ulcer healing through angiogenesis, fibroblast activation, and growth factor upregulation. Oral delivery concentrates these effects in the stomach and duodenum.

5. Gut Microbiome Disruption: Post-antibiotic gut recovery and dysbiosis — BPC-157 supports mucosal repair and appears to improve gut barrier function during microbiome reestablishment.

Mechanism in the GI Context

Oral BPC-157 triggers the same core repair mechanisms as injectable BPC-157, but with localized GI concentration: - Angiogenesis: VEGF upregulation and VEGFR2 signaling promote new blood vessel formation in healing GI mucosa — improving oxygen and nutrient delivery to repair sites - Tight junction restoration: Counteracts the tight junction disruption caused by inflammation, NSAIDs, alcohol, and stress - Growth factor cascade: Stimulates EGF (Epidermal Growth Factor), FGF (Fibroblast Growth Factor), and TGF-β expression locally in GI tissue - Motility normalization: Restores normal GI contractility in both hypomotility (ileus) and hypermotility (diarrhea) conditions through interaction with nitrergic and serotonergic systems - Anti-inflammatory: Modulates NF-κB and COX-2 expression in GI epithelial cells

Oral vs. Injectable: Choosing the Right Format

• **Oral capsules**: Preferred for GI conditions (leaky gut, IBD, GERD, ulcers, gut health maintenance)
• **Injectable BPC-157**: Preferred for systemic effects (musculoskeletal healing, neurological, systemic anti-inflammatory)
• **Combined protocol**: Some users run both simultaneously — oral for gut coverage, injectable for systemic repair